|
29 Oct 2013 |
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B
|
|
28 Oct 2013 |
Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel
|
|
28 Oct 2013 |
Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
|
|
28 Oct 2013 |
bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD
|
|
28 Oct 2013 |
MOLOGEN AG submitted clinical study with MGN1703 in small cell lung cance
|
|
27 Oct 2013 |
Medgenics Reports Positive Data with Second-Generation Viral Vectors at European Society of Gene and Cell Therapy Congress
|
|
22 Oct 2013 |
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
|
|
22 Oct 2013 |
Oncolytics Biotech® Inc. Announces Progression Free Survival Data for Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer
|
|
22 Oct 2013 |
StemCells, Inc. Announces Results of Long-Term Follow-Up Study in Batten Disease
|
